Alpha 2.0
Login Register
» Authors » Geert Jlh van Leenders

Geert Jlh van Leenders

Explore the profile of Geert Jlh van Leenders including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 89
Followers 0
Related Specialties
Pathology
Anatomy & Histology
General Medicine
Top 10 Co-Authors
Guido Jenster
Fritz H Schroder
Ries Kranse
Katrina Collins
A Marije Hoogland
Patrick Volland
Mark F Wildhagen
Matti Nykter
Roy G Masius
Andries M Bergman
Published In
Mod Pathol
Cases J
J Pathol Clin Res
Hum Pathol
medRxiv
Affiliations
Soon will be listed here.
Recent Articles
1.
4D pathology: translating dynamic epithelial tubulogenesis to prostate cancer pathology
Harikumar H, van Royen M, van Leenders G
Histopathology . 2024 Oct; 86(5):681-693. PMID: 39428716
The Gleason score is the gold standard for grading of prostate cancer (PCa) and is assessed by assigning specific grades to different microscopical growth patterns. Aside from the Gleason grades,...
2.
Fluorescence in-situ hybridization assessment of spindle cell-rich testicular sex cord stromal tumors demonstrates multiple chromosomal gains across histologic subtypes
Acosta A, Fletcher C, Sholl L, van Leenders G, Oliva E, Cornejo K, et al.
Hum Pathol . 2024 Sep; 153:105652. PMID: 39218045
Spindle cell-rich testicular sex cord-stromal tumors (TSCSTs) comprise a group that includes mostly (but not exclusively): myoid gonadal stromal tumor (MGST), adult granulosa cell tumor (AGCT), and unclassified TSCST. These...
3.
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing
Angeloni M, van Doeveren T, Lindner S, Volland P, Schmelmer J, Foersch S, et al.
J Pathol Clin Res . 2024 Mar; 10(2):e12369. PMID: 38504364
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive, yet understudied, urothelial carcinoma (UC). The more frequent UC of the bladder comprises several molecular subtypes, associated with different targeted...
4.
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Severson T, Zhu Y, Prekovic S, Schuurman K, Nguyen H, Brown L, et al.
medRxiv . 2023 Mar; PMID: 36865297
Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase II...
5.
Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer
Beukers W, Kandimalla R, Masius R, Vermeij M, Kranse R, van Leenders G, et al.
Mod Pathol . 2014 Nov; 28(4):515-22. PMID: 25394776
The potential risk of recurrence and progression in patients with non-muscle-invasive bladder cancer necessitates followup by cystoscopy. The risk of progression to muscle-invasive bladder cancer is estimated based on the...
6.
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
Hoogland A, Jenster G, van Weerden W, Trapman J, van der Kwast T, Roobol M, et al.
Mod Pathol . 2011 Nov; 25(3):471-9. PMID: 22080055
In prostate cancer genomic rearrangements involving genes encoding ETS transcription factors are commonly present, with androgen-regulated transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogen homologue (ERG) gene fusion occurring...
7.
Non-prostatic pathology on prostate needle-biopsy - colorectal carcinoid: a case report
van den Bergh R, Wolters T, Spaander M, Schroder F, van Leenders G
Cases J . 2009 Jan; 2(1):75. PMID: 19159470
Introduction: Prostate needle-biopsies are among the most common specimens in routine histopathological practice; in 15% colorectal tissue is also present. Rectal pathology is described to be found in 17% of...